BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 20197621)

  • 1. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
    Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
    J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
    J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
    Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
    Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
    Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
    Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
    Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression.
    Chang CJ; Mulholland DJ; Valamehr B; Mosessian S; Sellers WR; Wu H
    Mol Cell Biol; 2008 May; 28(10):3281-9. PubMed ID: 18332125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
    Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
    Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth.
    Wang L; Xiong H; Wu F; Zhang Y; Wang J; Zhao L; Guo X; Chang LJ; Zhang Y; You MJ; Koochekpour S; Saleem M; Huang H; Lu J; Deng Y
    Cell Rep; 2014 Sep; 8(5):1461-74. PubMed ID: 25176644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
    Wang G; Lunardi A; Zhang J; Chen Z; Ala U; Webster KA; Tay Y; Gonzalez-Billalabeitia E; Egia A; Shaffer DR; Carver B; Liu XS; Taulli R; Kuo WP; Nardella C; Signoretti S; Cordon-Cardo C; Gerald WL; Pandolfi PP
    Nat Genet; 2013 Jul; 45(7):739-746. PubMed ID: 23727861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.
    Zemskova M; Lilly MB; Lin YW; Song JH; Kraft AS
    Mol Cancer Res; 2010 Aug; 8(8):1126-41. PubMed ID: 20647331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
    Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
    Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
    Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
    Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.
    Song MS; Carracedo A; Salmena L; Song SJ; Egia A; Malumbres M; Pandolfi PP
    Cell; 2011 Jan; 144(2):187-99. PubMed ID: 21241890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
    Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
    PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
    Liu XS; Song B; Elzey BD; Ratliff TL; Konieczny SF; Cheng L; Ahmad N; Liu X
    J Biol Chem; 2011 Oct; 286(41):35795-35800. PubMed ID: 21890624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.